

SCHWERPUNKT: Erwachsene mit angeborenen Herzfehlern

- **Aktuelles zur Versorgungssituation von Erwachsenen mit angeborenem Herzfehler in Deutschland**

S. Freilinger, C. Andonian, P. Ewert, M. Huber, M. Huntgeburth, A.-S. Kaemmerer, N. Kohls, N. Nagdyman, R. Neidenbach, C. Röhrich, H. Kaemmerer

Literatur:

1. Neidenbach R et al. Medical care of adults with congenital heart diseases : Present and future. *Herz* 2019; 44(6): 553–72
2. Mandalenakis Z et al. Survival in Children With Congenital Heart Disease: Have We Reached a Peak at 97 *J Am Heart Assoc* 2020; 9(22): e017704
3. Seidel L et al. Facts about the General Medical Care of Adults with Congenital Heart Defects: Experience of a Tertiary Care Center. *J Clin Med* 2020; 9(6)
4. Benziger CP et al. Projected growth of the adult congenital heart disease population in the United States to 2050: an integrative systems modeling approach. *Popul Health Metr* 2015; 13: 29
5. Triedman JK & Newburger JW. Trends in Congenital Heart Disease: The Next Decade. *Circulation* 2016; 133(25): 2716–33
6. Perloff JK & Warnes CA. Challenges posed by adults with repaired congenital heart disease. *Circulation* 2001; 103(21): 2637–43
7. Neidenbach R et al. Improving medical care and prevention in adults with congenital heart disease-reflections on a global problem-part I: development of congenital cardiology, epidemiology, clinical aspects, heart failure, cardiac arrhythmia. *Cardiovasc Diagn Ther* 2018; 8(6): 705–15
8. Neidenbach R et al. Improving medical care and prevention in adults with congenital heart disease-reflections on a global problem-part II: infective endocarditis, pulmonary hypertension, pulmonary arterial hypertension and aortopathy. *Cardiovasc Diagn Ther* 2018; 8(6): 716–24
9. Neidenbach RC et al. Non-cardiac comorbidities in adults with inherited and congenital heart disease: report from a single center experience of more than 800 consecutive patients. *Cardiovasc Diagn Ther* 2018; 8(4): 423–31
10. Singh S et al. Extra-cardiac comorbidities or complications in adults with congenital heart disease: a nationwide inpatient experience in the United States. *Cardiovasc Diagn Ther* 2018; 8(6): 814–9
11. Andonian C et al. Current research status on the psychological situation of adults with congenital heart disease. *Cardiovasc Diagn Ther* 2018; 8(6): 799–804
12. Radke RM et al. Adult congenital heart disease and the COVID-19 pandemic. *Heart* 2020; 106(17): 1302–9
13. Kaemmerer H & Breithardt G. Recommendations for the quality improvement of interdisciplinary care of adults with congenital heart anomalies. *Clin Res Cardiol* 2006; 95 Suppl 4: 76–84

14. Hess J et al. Empfehlungen für Erwachsenen- und Kinderkardiologen zum Erwerb der Zusatz-Qualifikation „Erwachsene mit angeborenen Herzfehlern“ (EMAH) Clin Res Cardiol 2007; Suppl 2:19–26
15. Neidenbach R et al. Systematic Assessment of Health Care Perception in Adults with Congenital Heart Disease in Germany. CDT-Journal 2021
16. Kaemmerer A et al. Provision of medical health care for adults with congenital heart disease associated with aortic involvement. CDT-Journal 2021
17. Andonian C et al. Overweight and obesity: an emerging problem in patients with congenital heart disease. Cardiovasc Diagn Ther 2019; 9(Suppl 2): S360–S8
18. Baumgartner H & De Backer J. The ESC Clinical Practice Guidelines for the Management of Adult Congenital Heart Disease 2020. Eur Heart J 2020; 41(43): 4153–4
19. Deutsche Herzstiftung e.V. Deutscher Herzbericht 2019. 2020
20. Röhrich C & Kohls, N. Bedeutung von Prävention, Gesundheitsförderung und die Rolle des salutogenetischen Denkens in der Behandlung von chronischen Erkrankungen. Journal für angeborene Herzfehler 2019; 7, S80–5

- **Die Chirurgie der angeborenen Herzfehler im Erwachsenenalter**

J. Hörer, M. Strbad, E. Tonino, H. Kaemmerer, M. Ono, J. Cleuziou, P. Ewert, J. Pabst von Ohain

Literatur:

1. Khairy P et al. Changing mortality in congenital heart disease. J Am Coll Cardiol. 2010; 56: 1149-57
2. Mandalenakis Z et al. Survival in Children With Congenital Heart Disease: Have We Reached a Peak at 97%? J Am Heart Assoc 2020; 9: e017704
3. Beckmann A et al. German Heart Surgery Report 2019: The Annual Updated Registry of the German Society for Thoracic and Cardiovascular Surgery Thorac Cardiovasc Surg 2020; 68: 263–76
4. Hörer J et al. Evaluation of the Adult Congenital Heart Surgery Mortality Score at two European Centers. Ann Thorac Surg 2018; 105: 1441–6
5. Franklin RCG et al. Nomenclature for congenital and paediatric cardiac disease: the International Paediatric and Congenital Cardiac Code (IPCCC) and the Eleventh Iteration of the International Classification of Diseases (ICD-11). Cardiol Young 2017; 10: 1872–1938
6. van Gameren et al. Risk stratification for adult congenital heart surgery. Eur J Cardiothorac Surg 2010; 39: 490.49–4
7. Hörer J et al. Evaluation of the aristotle complexity models in adult patients with congenital heart disease. Eur J Cardiothorac Surg 2013; 43: 128–35
8. Beurtheret S et al. Contemporary cardiac surgery for adults with congenital heart disease. Heart 2017; 103: 1194–1202
9. Holst KA et al. Risk Factors and Early Outcomes of Multiple Reoperations in Adults With Congenital Heart Disease. Ann Thorac Surg 2011; 92: 122–30

10. O'Brien SM et al. An empirically based tool for analyzing mortality associated with congenital heart surgery. *J Thorac Cardiovasc Surg* 2009; 138: 1139–53
11. Hörer J et al. Mortality Following Congenital Heart Surgery in Adults Can Be Predicted Accurately by Combining Expert-Based and Evidence-Based Pediatric Risk Scores. *World J Pediatr Congenit Heart Surg* 2016; 7: 425–35
12. Fuller SM et al. Estimating Mortality Risk for Adult Congenital Heart Surgery: An Analysis of The Society of Thoracic Surgeons Congenital Heart Surgery Database. *Ann Thorac Surg* 2015; 100: 1728–35
13. Pabst von Ohain J et al. Risk Evaluation in Adult Congenital Heart Surgery: Analysis of the Society of Thoracic Surgeons – Congenital Heart Surgery Database Risk Models on Data from the European Congenital Heart Surgeons Association – Congenital Database. *Eur J Cardiothorac Surg*. akzeptiert zur Publikation, Januar 2021
14. Ranucci M et al. Accuracy, calibration and clinical performance of the EuroSCORE: can we reduce the number of variables? *Eur J Cardiothorac Surg* 2011 ;37: 724–9
15. Putman LM et al. Seventeen years of adult congenital heart surgery: a single centre experience. *Eur J Cardiothorac Surg* 2009; 36: 96–104
16. Hörer J et al. Validation of the Grown-Ups with Congenital Heart Disease Score. *Heart* 2018; 104: 1019–25

- **Das Marfan-Syndrom ist nicht nur eine Aorten- sondern auch eine Systemerkrankung**

Y. von Kodolitsch, M. Vogler, M. Huntgeburdt, R. M. Radke, K Kallenbach, P. Gehle, K. Szöcs

Literatur:

1. von Kodolitsch Y et al. Perspectives on the revised Ghent criteria for the diagnosis of Marfan syndrome. *The Appl Clin Genet* 2015; 8: 137–55
2. Manow ML et al. Analysis of Costs and Profits of Ambulatory Care of Marfan Patients after Initiation of a Novel German Legal Directive (section sign 116 b SGB V). *Med Klin (Munich)* 2010; 105: 529–37
3. Benninghoven D et al. Inpatient rehabilitation for adult patients with Marfan syndrome: an observational pilot study. *Orphanet J Rare Dis* 2017; 12: 127
4. van de Laar IMBH et al. European reference network for rare vascular diseases (VASCERN) consensus statement for the screening and management of patients with pathogenic ACTA2 variants. *Orphanet J Rare Dis* 2019; 14: 264-
5. Mühlstädt K et al. Case-matched Comparison of Cardiovascular Outcome in Loeys-Dietz Syndrome versus Marfan Syndrome. *J Clin Med* 2019; 8: E2079
6. von Kodolitsch Y et al. Features of Marfan syndrome not listed in the Ghent nosology – The Dark Side of the Disease. *Expert Rev Cardiovasc Ther* 2019: 10
7. De Paepe A et al. Revised diagnostic criteria for the Marfan syndrome. *Am J Med Genet* 1996; 62: 417–26
8. Marfan AB-J. Un cas de déformation congénital des quatre membres plus prononcée aux extrémités caractérisée par l'allongement des os avec un certain degré d'amonassment. *Bull Mem Soc Med Hop (Paris) Ser 3* 1896; 13: 220–6

9. Maumenee IH. The eye in the Marfan syndrome. *Birth Defects Orig Artic Ser* 1982; 18: 515-24
10. Williams E. Rare cases, with practical remarks. *Trans Am Ophthalmol Soc* 1875; 2: 291
11. Weve H. Über Arachnodakylie (Dystrophia mesodermalis congenita, Typus Marfan). *Arch Augenheilkd* 1931; 104: 1–46
12. Beighton P et al. International nosology of heritable disorders of connective tissue, Berlin, 1986. *Am J Med Genet* 1988; 29: 581–94
13. Murdoch JL et al. Life expectancy and causes of death in the Marfan syndrome. *N Engl J Med* 1972; 286: 804–8
14. Ting BL et al. The diagnostic value of the facial features of Marfan syndrome. *J Child Orthop* 2010; 4: 545–51
15. Rybczynski M et al. The spectrum of syndromes and manifestations in individuals screened for suspected Marfan syndrome. *Am J Med Genet* 2008; 146A: 3157–66
16. Nahum Y & Spierer A. Ocular features of Marfan syndrome: diagnosis and management. *Isr Med Assoc J* 2008; 10: 179–81
17. Child AH & Simonds AK. Pulmonary Manifestations of Marfan Syndrome. In: Child AH, editor. *Diagnosis and Management of Marfan Syndrome*. London: Springer London; 2016: 175-80
18. von Kodolitsch Y & Robinson PN. Die Lunge bei Marfan-Syndrom. *Das Marfan-Syndrom*. Berlin, Heidelberg: Springer Berlin Heidelberg; 2017: 133–7
19. Rybczynski M et al. Frequency and age-related course of mitral valve dysfunction in the marfan syndrome. *Am J Cardiol* 2010; 106: 1048–53
20. Sheikhzadeh S et al. Comprehensive analysis of dural ectasia in 150 patients with a causative FBN1 mutation. *Clin Genet* 2014; 86: 238–45
21. von Kodolitsch Y & Robinson PN. Die Dura bei Marfan. *Das Marfan-Syndrom*. Berlin, Heidelberg: Springer Berlin Heidelberg; 2017: 125–31
22. Al-Himdani S et al. Striae distensae: a comprehensive review and evidence-based evaluation of prophylaxis and treatment. *Br J Dermatol* 2014; 170: 527–47
23. Ledoux M et al. A case-control study of cutaneous signs in adult patients with Marfan disease: diagnostic value of striae. *J Am Acad Dermatol* 2011; 64: 290–5
24. Pyeritz RE. Chapter 153 – Marfan Syndrome and Related Disorders. In: Rimoin D, Korf RP, editors. *Emery and Rimoin's Principles and Practice of Medical Genetics (Sixth Edition)*. Oxford: Academic Press; 2013. 1–52
25. Dietz HC et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. *Nature* 1991; 352: 337–9
26. Cistulli PA & Sullivan CE. Influence of maxillary morphology on nasal airway resistance in Marfan's syndrome. *Acta Otolaryngol* 2000; 120: 410–3
27. Hyde LN. Dental Aspects of Marfan Syndrome. In: Child AH, editor. *Diagnosis and Management of Marfan Syndrome*. London: Springer London; 2016: 181–3
28. Cervino G et al. Oral health in patients with Marfan syndrome. *Arch Oral Biol* 2020; 116: 104745
29. Cistulli PA & Sullivan CE. Sleep disorders in Marfan's syndrome. *The Lancet* 1991; 337: 1359–60
30. Gessler N et al. Conservative therapy options for heritable thoracic aortic disorders (H-TAD). *Gefäßchirurgie* 2016; 21: 403–10
31. von Kodolitsch Y & Robinson PN. Bauchschmerz bei Marfan-Syndrom. *Das Marfan-Syndrom*. Berlin, Heidelberg: Springer Berlin Heidelberg; 2017: 139–42

32. Loughridge LW. Renal abnormalities in the Marfan syndrome. *Q J Med* 1959; 28: 531–44
33. Jabs C & Child AH. Genitourinary Tract in Women with Marfan Syndrome. In: Child AH, editor. *Diagnosis and Management of Marfan Syndrome*. London: Springer London; 2016: 219–25
34. Behan WMH et al. Muscle fibrillin deficiency in Marfan's syndrome myopathy. *J Neurol Neurosurg Psychiatry* 2003; 74: 633–8
35. Gray JR et al. Osteoporosis and the Marfan syndrome. *Postgrad Med J* 1993; 69: 373–5
36. Folkestad L et al. Fracture Rates and Fracture Risk in Patients With Marfan Syndrome: A Nationwide Register-Based Cohort Study. *J Bone Miner Res*
37. von Kodolitsch Y et al. The role of the multidisciplinary health care team in the management of patients with Marfan syndrome. *J Multidiscip Healthc* 2016; 9: 587–614
38. Sheikhzadeh S et al. A simple clinical model to estimate the probability of Marfan syndrome. *QJM* 2012; 105: 527–35
39. Kelly RE et al. Recent Modifications of the Nuss Procedure: The Pursuit of Safety During the Minimally Invasive Repair of Pectus Excavatum. *Ann Surg* 2020
40. Pepe G et al. Marfan syndrome: current perspectives. *Appl Clin Genet* 2016; 9: 55–65
41. Erbel R et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases. *Eur Heart J* 2014; 35: 2873–926
42. Kallenbach K et al. Aortic valve-sparing operation in Marfan syndrome: what do we know after a decade? *Ann Thorac Surg* 2007; 83: 764–8; discussion 85–90
43. Loeys BL et al. The revised Ghent nosology for the Marfan syndrome. *J Med Genet* 2010; 47: 476–85
44. <https://www.youtube.com/watch?v=gCgskmp8Riw>

- **Praxisrelevante Aspekte der Psychokardiologie für die Versorgung Erwachsener mit angeborenem Herzfehler**

C. Andonian, S. Freilinger, H. Kaemmerer, L. Pieper, C. Röhrich, N. Kohls, R. Neidenbach, M. Huber, P. Ewert, J. Beckmann

Literatur:

1. van der Linde D et al. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. *J Am Coll Cardiol* 2011; 58(21): 2241–7
2. Kaemmerer H et al. Angeborene Herzfehler: Zur Nachsorge ermuntern. *Hausarzt* 17 2014: 38–41
3. Kaemmerer H et al. Surgical treatment of patent ductus arteriosus: a new historical perspective. *Am J Cardiol* 2004; 94(9): 1153–4
4. Nagdyman N et al. Belastungen bei Erwachsenen mit angeborenen Herzfehlern (EMAH): Sport, Beruf, Familienplanung und Schwangerschaft. *Herzmedizin* 2016; 5: 16–26
5. Stout KK et al. 2018 AHA/ACC guideline for the management of adults with congenital heart disease: a report of the American College of

- Cardiology/American Heart Association task force on clinical practice guidelines. *Circulation* 2018
6. Lui G et al. on behalf of the American Heart Association Adult Congenital Heart Disease Committee of the Council on Clinical Cardiology and Council on Cardiovascular Disease in the Young; Council on Cardiovascular Radiology and Intervention; and Council on Quality of Care and Outcomes Research. Diagnosis and management of noncardiac complications in adults with congenital heart disease: a scientific statement from the American Heart Association. *Circulation* 2017
 7. Neidenbach RC et al. Non-cardiac comorbidities in adults with inherited and congenital heart disease: report from a single center experience of more than 800 consecutive patients. *Cardiovasc Diagn Ther* 2018
 8. Neidenbach R et al. Striking supply gap in adults with congenital heart disease? *Deutsche medizinische Wochenschrift* 2017; 142(4): 301–3
 9. Jackson JL et al. Depressive and anxiety symptoms in adult congenital heart disease: Prevalence, health impact and treatment. *Prog Cardiovasc Dis* 2018
 10. Pauliks LB. Depression in adults with congenital heart disease-public health challenge in a rapidly expanding new patient population. *World J Cardiol* 2013; 5(6): 186
 11. Deng LX et al. Prevalence and correlates of post-traumatic stress disorder in adults with congenital heart disease. *Am J Cardiol* 2016; 117(5): 853–7
 12. Kaemmerer H et al. Psychosocial problems of adolescents and adults with congenital heart defects. *Zeitschrift für Kardiologie*. 1994;83(3):194-200.
 13. Kronwittter A et al. Psychosocial situation in adults with congenital heart defects today and 20 years ago: Any changes? *Int J Cardiol* 2018
 14. Mücke K. Probleme sind Lösungen: systemische Beratung und Psychotherapie-ein pragmatischer Ansatz; Lehr-und Lernbuch: Mücke, Ökosysteme-Verlag; 2003
 15. Titscher G. Praxisfelder in der Psychokardiologie. *PiD-Psychotherapie im Dialog* 2011; 12(01): 8–12
 16. Kovacs AH et al. Biopsychosocial experiences of adults with congenital heart disease: review of the literature. *Am Heart J* 2005; 150(2): 193–201
 17. Callus E et al. Elements of psychocardiology in the psychosocial handling of adults with congenital heart disease. *Front Psychol* 2010; 1: 34
 18. Andonian C et al. Current research status on the psychological situation of adults with congenital heart disease. *Cardiovasc Diagn Ther* 2018; 8(6): 799
 19. Albus C et al. Psychosomatische Problemfelder und Komorbiditäten am Beispiel der koronaren Herzkrankheit. *Psychokardiologie: Springer*; 2020: 59–117
 20. Albus C. Grundkonzepte der psychosomatischen Medizin. *Psychokardiologie: Springer*; 2020: 39–46
 21. Eslami B et al. Anxiety, depressive and somatic symptoms in adults with congenital heart disease. *J psychosom Res* 2013; 74(1): 49–56
 22. Hoyer J & Lueken U. Herzangst. *PiD-Psychotherapie im Dialog* 2011; 12(01): 70–4
 23. Köllner V et al. Angst, Herzkrankheit und Verhaltenstherapie. *PiD-Psychotherapie im Dialog* 2011; 12(01) :23–8
 24. Lichtman JH et al. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association. *Circulation* 2014

25. Park J-H et al. Depression and anxiety as predictors of recurrent cardiac events 12 months after percutaneous coronary interventions. *J Cardiovasc Nurs* 2015; 30(4): 351–9
26. Watkins LL et al. Association of anxiety and depression with all-cause mortality in individuals with coronary heart disease. *J Am Heart Assoc* 2013; 2(2): e000068
27. Andonian C et al. Overweight and obesity: an emerging problem in patients with congenital heart disease. *Cardiovasc Diagn Ther* 2019
28. Lane D et al. Quality of life in adults with congenital heart disease. *Heart* 2002; 88(1): 71–5
29. Moons P et al. Individual quality of life in adults with congenital heart disease: a paradigm shift. *Eur Heart J* 2004; 26(3): 298–307
30. Oris L et al. Illness identity in adults with a chronic illness. *J Clin Psychol Med Settings* 2018: 1–12
31. Andonian C et al. Assessment of the Psychological Situation in Adults with Congenital Heart Disease. *J Clin Med* 2020; 9(3): 779
32. Van Bulck L et al. Illness Identity: A Novel Predictor for Healthcare Use in Adults With Congenital Heart Disease. *J Am Heart Assoc* 2018; 7(11): e008723
33. Bernd B. Die psychischen Folgen chronischer Krankheit im Kindes- und Jugendalter. In: Petermann F, editor. *Chronische Krankheiten bei Kindern und Jugendlichen*. Berlin: Quintessenz; 1994: 11–28
34. Herrmann-Lingen C. Biopsychosoziale Faktoren in Genese und Manifestation der koronaren Herzkrankheit/Biopsychosocial factors in pathogenesis and manifestation of coronary heart disease. *Zeitschrift für Psychosomatische Medizin und Psychotherapie* 2000; 46(4): 315–30

- **Salutogenese: Benefit in der Behandlung von Erwachsenen mit angeborenen Herzfehlern?**

C. Röhrich, C. Andonian, M. Huber, H. Kaemmerer, J. Beckmann, N. Kohls

Literatur:

1. Seidel L et al. Facts about the General Medical Care of Adults with Congenital Heart Defects: Experience of a Tertiary Care Center. *J Clin Med* 2020; 9
2. Neidenbach R et al. Systematic assessment of health care perception in adults with congenital heart disease in Germany. *Cardiovasc Diagn Ther* 2021; 11: 481–491
3. Neidenbach R et al. Erwachsene mit angeborenen Herzfehlern – Eklatante Versorgungslücke? *Deutsche medizinische Wochenschrift (1946)* 2017; 142: 301–303
4. Warnes CA. Adult congenital heart disease: the challenges of a lifetime. *Eur heart J* 2017; 38: 2041–2047
5. Singh S et al. Extra-cardiac comorbidities or complications in adults with congenital heart disease: a nationwide inpatient experience in the United States. *Cardiovasc Diagn Ther* 2018; 8: 814–819

6. Neidenbach RC et al. Non-cardiac comorbidities in adults with inherited and congenital heart disease: report from a single center experience of more than 800 consecutive patients. *Cardiovasc Diagn Ther* 2018; 8: 423–431
7. Kaemmerer H & Kodolitsch Y von. Current management aspects in adult congenital heart disease: heading for the future. *Cardiovasc Diagn Ther* 2018; 8: 696–697
8. Lee M-J & Jung D. Development and effects of a self-management efficacy promotion program for adult patients with congenital heart disease. *European journal of cardiovascular nursing: journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology* 2019; 18: 140–148
9. Rosenthal TM et al. Lifestyle Modification for the Prevention of Morbidity and Mortality in Adult Congenital Heart Disease. *Congenit Heart Dis* 2016: 189–198
10. Kalitzkus V et al. Narrative Medizin - was ist es, was bringt es, wie setzt man es um? *Zeitschrift für Allgemeinmedizin*; 85: 60–66
11. Andonian C et al. Assessment of the Psychological Situation in Adults with Congenital Heart Disease. *J Clin Med* 2020; 9
12. Herrmann-Lingen C & Meinertz T. Psychosomatik der koronaren Herzkrankheit. *Internist* 2010; 51: 826–835
13. Watkins LL et al. Association of anxiety and depression with all-cause mortality in individuals with coronary heart disease. *J Am Heart Assoc* 2013; 2: e000068
14. Albus C et al. Bedeutung von psychosozialen Faktoren in der Kardiologie – Update 2018. *Kardiologie* 2018; 12: 312–331
15. Röhrich C et al. Narrative view of the role of health promotion and salutogenesis in the treatment of chronic disease: viability and value for the care of cardiovascular conditions. *Cardiovasc Diagn Ther* 2021; 11: 591–601
16. Erster Bericht der Nationalen Präventionskonferenz über die Entwicklung der Gesundheitsförderung und Prävention (Erster Präventionsbericht); Stand Juni 2019
17. World Health Organization. Preamble to the Constitution of the World Health Organization. International Health Conference 19-22 June 1946. New York; 1948
18. Franke A. Modelle von Gesundheit und Krankheit. 3. Aufl. Bern: Huber; 2012
19. Antonovsky A. Unraveling the mystery of health. How people manage stress and stay well. 1. Aufl. San Francisco: Jossey-Bass; 1988
20. Petzold TD & Bahrs O. Beiträge der Salutogenese zu Forschung, Theorie und Professionsentwicklung im Gesundheitswesen. In: Kriwy P, Jungbauer-Gans M, Hrsg. *Handbuch Gesundheitssoziologie*. Wiesbaden: Springer Fachmedien Wiesbaden; 2020: 89–116
21. Noack RH. Salutogenese: Ein neues Paradigma in der Medizin? In: Bartsch HH, Bengel J, Hrsg. *Salutogenese in der Onkologie*. Basel: Karger; 1997: 88–105
22. Schwarzer R. Modeling Health Behavior Change: How to Predict and Modify the Adoption and Maintenance of Health Behaviors. *Appl Psychol* 2008; 57: 1–29
23. Sachse R. Klärungsorientierte Psychotherapie. Göttingen: Hogrefe Verl. für Psychologie; 2003
24. Brandstätter V et al. *Motivation und Emotion*. Berlin, Heidelberg: Springer Berlin Heidelberg; 2013
25. Waters D & Sierpina VS. Goal-Directed Health Care and the chronic pain patient: a new vision of the healing encounter. *Pain physician* 2006: 353–360

26. Hood L. P4 Medicine and Scientific Wellness: Catalyzing a Revolution in 21st Century Medicine. *Mol Front J* 2017; 01: 132–137

- **Die Aorta bei angeborenen Herzfehlern – ein vernachlässigtes Organ**

M. Huntgeburth, A.-S. Kaemmerer, C. Meierhofer, S. Freilinger, P. Ewert, Y. von Kodolitsch

Literatur:

1. Mutluer FO & Celiker A. General Concepts in Adult Congenital Heart Disease. *Balkan Med J* 2018; 35(1): 18–29
2. van der Linde D et al. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. *J Am Coll Cardiol* 2011; 58(21): 2241–7
3. Wren C, O'Sullivan JJ. Survival with congenital heart disease and need for follow up in adult life. *Heart* 2001; 85(4): 438–43
4. Baumgartner H et al. 2020 ESC Guidelines for the management of adult congenital heart disease. *Eur Heart J* 2021; 42(6): 563–645
5. Neidenbach R et al. Improving medical care and prevention in adults with congenital heart disease-reflections on a global problem-part I: development of congenital cardiology, epidemiology, clinical aspects, heart failure, cardiac arrhythmia. *Cardiovasc Diagn Ther* 2018; 8(6): 705–15
6. Khairy P et al. Changing mortality in congenital heart disease. *J Am Coll Cardiol* 2010; 56(14): 1149–57
7. Erikssen G et al. Achievements in congenital heart defect surgery: A prospective, 40 year study of 7038 patients. *Circulation* 2015 ;131(4): 337–46; discussion 46
8. Stout KK et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: Executive Summary. *Circulation* 2018
9. Neidenbach RC et al. Non-cardiac comorbidities in adults with inherited and congenital heart disease: report from a single center experience of more than 800 consecutive patients. *Cardiovasc Diagn Ther* 2018; 8(4): 423–31
10. Singh S et al. Extra-cardiac comorbidities or complications in adults with congenital heart disease: a nationwide inpatient experience in the United States. *Cardiovasc Diagn Ther.* 2018; 8(6): 814–9
11. Lui GK et al. Risk Estimates for Atherosclerotic Cardiovascular Disease in Adults With Congenital Heart Disease. *Am J Cardiol* 2017; 119(1): 112–8
12. Lui GK et al. Diagnosis and Management of Noncardiac Complications in Adults With Congenital Heart Disease: A Scientific Statement From the American Heart Association. *Circulation* 2017; 136(20): e348–e92
13. Perloff JK & Warnes CA. Challenges posed by adults with repaired congenital heart disease. *Circulation* 2001; 103(21): 2637–43
14. Warnes CA. The adult with congenital heart disease: born to be bad? *J Am Coll Cardiol* 2005; 46(1): 1–8
15. Neidenbach R et al. Improving medical care and prevention in adults with congenital heart disease-reflections on a global problem-part II: infective

- endocarditis, pulmonary hypertension, pulmonary arterial hypertension and aortopathy. *Cardiovasc Diagn Ther* 2018; 8(6): 716–24
16. Erbel R et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). *Eur Heart J* 2014; 35(41): 2873–926
 17. Neidenbach R et al. Medical care of adults with congenital heart diseases : Present and future. *Herz* 2019; 44(6): 553–72
 18. Kaemmerer AS FS et al. Provision of medical health care for adults with congenital heart disease associated with aortic involvement. *Cardiovasc Diagn Ther* 2021 (in print)
 19. Kuijpers JM & Mulder BJ. Aortopathies in adult congenital heart disease and genetic aortopathy syndromes: management strategies and indications for surgery. *Heart* 2017
 20. Niwa K et al. editors. Tokyo: Springer Japan; 2017.
 21. von Kodolitsch Y et al. The role of the multidisciplinary health care team in the management of patients with Marfan syndrome. *Journal of multidisciplinary healthcare* 2016; 9: 587
 22. Niwa K et al. Structural abnormalities of great arterial walls in congenital heart disease: light and electron microscopic analyses. *Circulation* 2001; 103(3): 393–400
 23. Niwa K. Aortopathy in Congenital Heart Disease in Adults: Aortic Dilatation with Decreased Aortic Elasticity that Impacts Negatively on Left Ventricular Function. *Korean Circ J* 2013; 43(4): 215–20
 24. Zanjani KS & Niwa K. Aortic dilatation and aortopathy in congenital heart diseases. *J Cardiol* 2013;61(1):16–21.
 25. Niwa K. Aortic dilatation in complex congenital heart disease. *Cardiovasc Diagn Ther.* 2018; 8(6): 725–38
 26. Niwa K. Aortic root dilatation in tetralogy of Fallot long-term after repair-- histology of the aorta in tetralogy of Fallot: evidence of intrinsic aortopathy. *Int J Cardiol* 2005; 103(2): 117–9
 27. Zaidi AN et al. Aortopathy in Adults with Congenital Heart Disease. In: Da Cruz E., Ivy D., J. J, editors. *Pediatric and Congenital Cardiology, Cardiac Surgery and Intensive Care*. London: Springer; 2014: 2651–68
 28. Francois K. Aortopathy associated with congenital heart disease: A current literature review. *Ann Pediatr Cardiol* 2015; 8(1): 25–36
 29. Senzaki H et al. Arterial haemodynamics in patients after repair of tetralogy of Fallot: influence on left ventricular after load and aortic dilatation. *Heart* 2008; 94(1): 70–4
 30. Di Salvo G et al. Imaging the adult with congenital heart disease: a multimodality imaging approach-position paper from the EACVI. *Eur Heart J Cardiovasc Imaging* 2018; 19(10): 1077–98
 31. Lang RM et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging* 2015; 16(3): 233–70

32. Pennig L et al. Comparison of a novel Compressed SENSE accelerated 3D modified relaxation-enhanced angiography without contrast and triggering with CE-MRA in imaging of the thoracic aorta. *Int J Cardiovasc Imaging* 2021; 37(1): 315–29
33. von Kodolitsch Y & Kutsche K. Genetic diagnostics of inherited aortic diseases : Medical strategy analysis. *Herz* 2017; 42(5): 459–67
34. Loeys BL et al. The revised Ghent nosology for the Marfan syndrome. *J Med Genet* 2010; 47(7): 476–85
35. Rampoldi V et al. Simple risk models to predict surgical mortality in acute type A aortic dissection: the International Registry of Acute Aortic Dissection score. *Ann Thorac Surg* 2007; 83(1): 55–61
36. Shores J et al. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. *N Engl J Med* 1994; 330(19): 1335–41
37. Groenink M et al. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. *Eur Heart J* 2013; 34(45): 3491–500
38. Doyle JJ et al. A deleterious gene-by-environment interaction imposed by calcium channel blockers in Marfan syndrome. *Elife* 2015; 4
39. Singh MN & Lacro RV. Recent Clinical Drug Trials Evidence in Marfan Syndrome and Clinical Implications. *Can J Cardiol* 2016; 32(1): 66–77
40. Kallenbach K & von Kodolitsch Y. Die Aorta bei Marfan. *Das Marfan-Syndrom*. Berlin, Heidelberg: Springer Berlin Heidelberg; 2017: 75–85
41. Von Kodolitsch Y et al. Perspectives on the revised Ghent criteria for the diagnosis of Marfan syndrome. *Appl Clin Genet* 2015; 8: 137
42. Neidenbach R et al. Striking Supply Gap in Adults with Congenital Heart Disease?. *Dtsch Med Wochenschr* 2017; 142(4): 301–3
43. Neidenbach R et al. Adults with congenital heart disease: lack of specific disease related medical health care from the patients point of view. *Eur Heart J* 2018; 39: 111
44. Neidenbach R et al. Adults with congenital heart disease: lack of specific disease related medical health care from the general practitioners view. *Eur Heart J* 2018; 39: 112
45. Seidel L et al. Facts about the General Medical Care of Adults with Congenital Heart Defects: Experience of a Tertiary Care Center. *J Clin Med* 2020; 9(6)
46. Benninghoven D et al. Inpatient rehabilitation for adult patients with Marfan syndrome: an observational pilot study. *Orphanet J Rare Dis* 2017; 12(1): 127

ZUSATZARTIKEL: Morbus Fabry

- **Morbus Fabry – wichtige Informationen für Kardiologen über ein seltenes Krankheitsbild**

I. Mattig, D. Frumkin , C. Tillmanns, K. Klingel, S. Cnaan-Kühl, F. Knebel

Literatur:

1. Anderson GR. NOTE on a CASE of PERFORATED GASTRIC ULCER. *Br Med J* 1898; 1(1953): 1448–9

2. F. J. Purpura Papulosa haemorrhagica Hebrae. Arch Derm Syph 1898(1898): 188–200
3. Desnick RJ et al. Fabry disease (alpha-galactosidase A deficiency): renal involvement and enzyme replacement therapy. Contrib Nephrol 2001(136): 174–92
4. Opitz JM et al. The Genetics of Angiokeratoma Corporis Diffusum (Fabry's Disease) and Its Linkage Relations with the Xg Locus. Am J Hum Genet 1965; 17(4): 325–42
5. Beck M et al. Anderson-Fabry disease in children and adolescents. Contrib Nephrol 2001(136): 251–5
6. Whybra C et al. Clinical manifestation in female Fabry disease patients. Contrib Nephrol 2001(136): 245–50
7. Koulousios K et al. Fabry disease due to D313Y and novel GLA mutations. BMJ Open 2017; 7(10): e017098
8. Eng CM et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 2007; 30(2): 184–92
9. Germain DP. Fabry disease. Orphanet J Rare Dis 2010; 5: 30
10. Grau AJ et al. Fabry's disease: new therapeutic options for this lysosomal storage disorder. Nervenarzt 2003; 74(6): 489–96
11. Mehta A et al. Fabry disease: a review of current management strategies. QJM 2010; 103(9): 641–59
12. MacDermot KD et al. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001; 38(11): 750–60
13. Ortiz A et al. Fabry disease revisited: Management and treatment recommendations for adult patients. Mol Genet Metab 2018; 123(4): 416–27
14. MacDermot J & MacDermot KD. Neuropathic pain in Anderson-Fabry disease: pathology and therapeutic options. Eur J Pharmacol 2001; 429(1-3): 121–5
15. MacDermot KD et al. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001; 38(11): 769–75
16. Hughes DA. Fabry disease: will markers of early disease enable early treatment and better outcomes? Curr Opin Cardiol 2016; 31(4): 434–9
17. Linhart A et al. An expert consensus document on the management of cardiovascular manifestations of Fabry disease. Eur J Heart Fail 2020; 22(7): 1076–96
18. Namdar M et al. Electrocardiographic changes in early recognition of Fabry disease. Heart 2011; 97(6): 485–90
19. Niemann M et al. Cross-sectional baseline analysis of electrocardiography in a large cohort of patients with untreated Fabry disease. J Inherit Metab Dis 2013; 36(5): 873–9
20. Namdar M et al. Value of electrocardiogram in the differentiation of hypertensive heart disease, hypertrophic cardiomyopathy, aortic stenosis, amyloidosis, and Fabry disease. Am J Cardiol 2012; 109(4): 587–93
21. Augusto JB et al. The myocardial phenotype of Fabry disease pre-hypertrophy and pre-detectable storage. Eur Heart J Cardiovasc Imaging 2020
22. Shah JS et al. Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol 2005; 96(6): 842–6

23. Niemann M et al. Prominent papillary muscles in Fabry disease: a diagnostic marker? *Ultrasound Med Biol* 2011; 37(1): 37–43
24. Marek J et al. Comparison of echocardiographic parameters in Fabry cardiomyopathy and light-chain cardiac amyloidosis. *Echocardiography* 2018; 35(11): 1755–63
25. Sado DM et al. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. *Circ Cardiovasc Imaging* 2013; 6(3): 392–8
26. Kramer J et al. Two-dimensional speckle tracking as a non-invasive tool for identification of myocardial fibrosis in Fabry disease. *Eur Heart J* 2013; 34(21): 1587–96
27. Hughes DA et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. *Heart* 2008; 94(2): 153–8
28. Mehta A et al. Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. *Lancet* 2009; 374(9706): 1986–96
29. Schiffmann R et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. *JAMA* 2001; 285(21): 2743–9
30. Schiffmann R. Neuropathy and Fabry disease: pathogenesis and enzyme replacement therapy. *Acta Neurol Belg* 2006; 106(2): 61–5
31. Germain DP et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. *J Am Soc Nephrol* 2007; 18(5): 1547–57
32. Germain DP et al. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. *J Med Genet* 2015; 52(5): 353–8
33. Tondel C et al. Agalsidase benefits renal histology in young patients with Fabry disease. *J Am Soc Nephrol* 2013; 24(1): 137–48
34. Skrunes R et al. Reaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients. *Nephrol Dial Transplant* 2017; 32(5): 807–13
35. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, et al. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. *N Engl J Med* 2001; 345(1): 9–16
36. Rombach SM et al. Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages. *J Inher Metab Dis* 2014; 37(3): 341–52
37. Linthorst GE et al. Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. *Kidney Int* 2004; 66(4): 1589–95
38. Biegstraaten M et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. *Orphanet J Rare Dis* 2015; 10: 36
39. Schiffmann R et al. Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year Phase 1/2 clinical trial. *J Inher Metab Dis* 2019; 42(3): 534–44
40. Benjamin ER et al. The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat. *Genet Med* 2017; 19(4): 430–8

41. Rote Liste. <https://www.rote-liste.de/suche/praep/26648/Galafold%20123%20mg%20Hartkapseln>. 2020; Zugriff am 14.11.2020
42. Germain DP et al. Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat. *N Engl J Med* 2016; 375(6): 545–55
43. Hughes DA, et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. *J Med Genet* 2017; 54(4): 288–96
44. Germain DP GR et al. Efficacy of migalastat in a cohort of male patients with the classic Fabry phenotype in the FACETS phase 3 study. *Mol Genet Metab* 2017; 20(1): S52
45. Guerard N et al. Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects. *Orphanet J Rare Dis* 2017; 12(1): 9
46. AvroBio. Open-Label, Study Of Efficacy and Safety Of AVR-RD-01 for Treatment - Naive Subjects With Classic Fabry Disease. <https://clinicaltrials.gov/ct2/show/NCT03454893>. 2018; Zugriff am 14.11.20